Wasner G, Simons S S
Steroid Hormones Section, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.
Mol Endocrinol. 1987 Jan;1(1):109-20. doi: 10.1210/mend-1-1-109.
The two independently derived hepatoma cell lines (HTC and Fu5-5) have previously been shown to display different sensitivities for the induction of tyrosine aminotransferase (TAT) enzyme activity and mRNA levels by glucocorticoids with the enzyme being half-maximally induced at approximately 7-fold higher concentrations of dexamethasone in HTC cells than in Fu5-5 cells. In the present study we investigated the induction of TAT activity by cAMP in order to see whether the difference is limited to the steroidal induction. Using the stable cAMP derivative (8-(4-chlorophenylthio)-cAMP) as an inducer, we found that a 6-fold higher cAMP concentration was needed in HTC cells to achieve the same extent of enzyme induction as in Fu5-5 cells. The induction of TAT enzyme activity could be accounted for by an increased amount of TAT mRNA. Further experiments involving sequential addition of both inducers in general showed a synergism of steroids and cAMP for TAT induction in HTC cells only at submaximal concentrations of steroid; in Fu5-5 cells, the occurrence of synergism depended on the order of addition of inducers. The maximal response in HTC cells was limited to the value that could be achieved by induction with steroid alone. In Fu5-5 cells, however, the steroid response could be augmented when cAMP was added to cells already maximally induced by steroid. This demonstrates that the effect of a combination of cAMP and steroids depends on their concentration, the sequence of their addition, and the rat hepatoma cell line used. Collectively the data suggest that a common pretranslational event determines the differential sensitivity of TAT induction by glucocorticoids and by cAMP in HTC and Fu5-5 cells. Furthermore a second, or possibly the same, common event also regulates the maximum level of TAT induction that is obtainable under most conditions with glucocorticoids and/or cAMP.
先前已表明,两种独立衍生的肝癌细胞系(HTC和Fu5-5)对糖皮质激素诱导酪氨酸转氨酶(TAT)酶活性和mRNA水平表现出不同的敏感性,HTC细胞中诱导该酶活性达到最大值时所需的地塞米松浓度比Fu5-5细胞中约高7倍。在本研究中,我们研究了cAMP对TAT活性的诱导作用,以确定这种差异是否仅限于甾体诱导。使用稳定的cAMP衍生物(8-(4-氯苯硫基)-cAMP)作为诱导剂,我们发现HTC细胞中需要比Fu5-5细胞高6倍的cAMP浓度才能达到相同程度的酶诱导。TAT酶活性的诱导可归因于TAT mRNA量的增加。进一步的实验涉及依次添加两种诱导剂,总体上显示,仅在甾体亚最大浓度时,甾体和cAMP在HTC细胞中对TAT诱导具有协同作用;在Fu5-5细胞中,协同作用的发生取决于诱导剂添加的顺序。HTC细胞中的最大反应仅限于单独用甾体诱导所能达到的值。然而,在Fu5-5细胞中,当将cAMP添加到已被甾体最大诱导的细胞中时,甾体反应可以增强。这表明cAMP和甾体组合的作用取决于它们的浓度、添加顺序以及所使用的大鼠肝癌细胞系。总体而言,数据表明,一个共同的翻译前事件决定了HTC和Fu5-5细胞中糖皮质激素和cAMP对TAT诱导的差异敏感性。此外,第二个或可能相同的共同事件也调节了在大多数情况下用糖皮质激素和/或cAMP可获得的TAT诱导的最大水平。